News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck KGaA’s Erbitux Gets Green Light for Head Cancer
October 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, Oct 24 (Reuters) - A committee of experts advising the European Commission said on Friday it backed Merck KGaA's Erbitux drug for a second use to combat head and neck cancer, bolstering its sales potential in the region.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
·
2 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
February 23, 2026
·
1 min read
·
Annalee Armstrong
